CLEVELAND, April 16 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (Nasdaq: CBLI - News; BSE: CFB - News), announced today a letter to supporters and stakeholders from its President and CEO, Michael Fonstein, Ph.D., providing a progress report on clinical and corporate developments since the previous update published in October 2006. The letter is included in its entirety below:
